Name: Saroglitazar in Primary biliary cholangitis: Product comparison
Published: 2026-09-14T15:39:06-04:00

Product information and disease description Product description Product information

Product comparison

7 evidence topics · 8 sources

PPAR-agonist systematic review

“Based on subgroup analysis, Bezafibrate, Seladelpar, and Saroglitazar significantly reduced GGT levels.” (opens the source at this quote in a new tab)
“Saroglitazar in one study(s)” (opens the source at this quote in a new tab)

Network meta-analysis including saroglitazar

“Due to the higher incidence of elevated liver enzymes observed with the 4 mg dose, saroglitazar at doses of 2 mg was included.” (opens the source at this quote in a new tab)

PPAR-agonist meta-analysis

“Eight RCTs involving 869 participants in total were included.” (opens the source at this quote in a new tab)

Comparator network meta-analysis

“The NMA included three studies, each testing obeticholic acid (OCA), seladelpar or elafibranor versus placebo” (opens the source at this quote in a new tab)

Second-line therapy network meta-analysis

“Twelve RCTs comprising 1,540 patients (therapy lengths 12–52 weeks) were included.” (opens the source at this quote in a new tab)
“PPAR agonists (bezafibrate, seladelpar, elafibranor, saroglitazar)” (opens the source at this quote in a new tab)

PPAR-targeted therapy review

“Saroglitazar, a dual PPAR-α/γ agonist, showed no effect on pruritus in phase 2; however, the sample size was small.” (opens the source at this quote in a new tab)

Emerging-therapy review

“This review summarizes the current literature regarding the new and emerging therapies for patients with PBC.” (opens the source at this quote in a new tab)